In our study, we investigated the therapeutic effects of KV to inhibit the growth and proliferation of KRAS-mutated pancreatic cancer cell lines (AsPC-1, Panc-1, and MiaPaCa-2) and oxaliplatin-resistant pancreatic cancer cells (oxaliplatin-resistant AsPC-1 cells). Here, KRAS is linked to familial pancreatic carcinoma.